STOCK TITAN

Kyverna Therapeutics Announces Leadership Update

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags

Kyverna Therapeutics (KYTX) announced key leadership changes. Warner Biddle has been appointed as the new Chief Executive Officer and Board member, replacing Peter Maag. Biddle brings over 30 years of experience in commercial and franchise leadership, including successful CAR T therapy launches at Kite Pharma. Christi Shaw, a seasoned life sciences executive, joins the Board of Directors, succeeding Brian Kotzin.

These appointments aim to strengthen Kyverna's leadership as it advances its CAR T cell therapies for autoimmune diseases. The company's lead candidate, KYV-101, is progressing into later development stages. Biddle's experience in commercializing cell therapies and Shaw's broad industry expertise are expected to guide Kyverna through its next growth phase, focusing on market preparation and expansion in the autoimmune disease space.

Kyverna Therapeutics (KYTX) ha annunciato importanti cambiamenti nella leadership. Warner Biddle è stato nominato nuovo Amministratore Delegato e membro del Consiglio, sostituendo Peter Maag. Biddle porta con sé oltre 30 anni di esperienza nella leadership commerciale e di franchising, inclusi lanci di successo di terapie CAR T presso Kite Pharma. Christi Shaw, un'esperta dirigente nel settore delle scienze della vita, entra nel Consiglio di Amministrazione, succedendo a Brian Kotzin.

Queste nomine mirano a rafforzare la leadership di Kyverna mentre avanza con le sue terapie cellulari CAR T per le malattie autoimmuni. Il candidato principale dell'azienda, KYV-101, sta progredendo verso le fasi di sviluppo avanzato. L'esperienza di Biddle nella commercializzazione delle terapie cellulari e l'ampia esperienza di Shaw nel settore si prevede guideranno Kyverna nella sua prossima fase di crescita, con un focus sulla preparazione e l'espansione nel mercato delle malattie autoimmuni.

Kyverna Therapeutics (KYTX) anunció cambios clave en el liderazgo. Warner Biddle ha sido nombrado nuevo Director Ejecutivo y miembro de la Junta, reemplazando a Peter Maag. Biddle aporta más de 30 años de experiencia en liderazgo comercial y de franquicia, incluidos lanzamientos exitosos de terapias CAR T en Kite Pharma. Christi Shaw, una experimentada ejecutiva de ciencias de la vida, se une a la Junta Directiva, sucediendo a Brian Kotzin.

Estos nombramientos tienen como objetivo fortalecer el liderazgo de Kyverna a medida que avanza en sus terapias con células CAR T para enfermedades autoinmunes. El candidato principal de la compañía, KYV-101, está progresando hacia etapas de desarrollo más avanzadas. Se espera que la experiencia de Biddle en la comercialización de terapias celulares y la amplia experiencia de Shaw en la industria guíen a Kyverna a través de su próxima fase de crecimiento, centrándose en la preparación y expansión del mercado en el ámbito de las enfermedades autoinmunes.

Kyverna Therapeutics (KYTX)가 주요 리더십 변화를 발표했습니다. Warner Biddle이 새로운 CEO 및 이사로 임명되어 Peter Maag를 대체합니다. Biddle은 Kite Pharma에서 성공적인 CAR T 치료제를 출시한 경험을 포함하여 30년 이상의 상업 및 프랜차이즈 리더십 경험을 제공합니다. Christi Shaw, 생명 과학 분야의 노련한 임원이 Brian Kotzin의 후임으로 이사회에 합류합니다.

이러한 임명은 Kyverna가 자가면역 질환에 대한 CAR T 세포 치료제를 발전시키는 과정에서 리더십을 강화하는 것을 목표로 합니다. 회사의 주요 후보인 KYV-101은 후속 개발 단계로 진행 중입니다. Biddle의 세포 치료제 상용화 경험과 Shaw의 폭넓은 산업 전문성이 Kyverna가 자가면역 질환 시장에서의 준비와 확장에 집중하며 다음 성장 단계를 안내할 것으로 예상됩니다.

Kyverna Therapeutics (KYTX) a annoncé des changements clés dans sa direction. Warner Biddle a été nommé nouveau Directeur Général et membre du Conseil d'Administration, remplaçant Peter Maag. Biddle a plus de 30 ans d'expérience en leadership commercial et de franchise, y compris des lancements réussis de thérapies CAR T chez Kite Pharma. Christi Shaw, une dirigeante chevronnée des sciences de la vie, rejoint le Conseil d'Administration, succédant à Brian Kotzin.

Ces nominations visent à renforcer le leadership de Kyverna alors que l'entreprise fait avancer ses thérapies cellulaires CAR T pour les maladies auto-immunes. Le candidat principal de l'entreprise, KYV-101, progresse vers des étapes de développement avancées. L'expérience de Biddle dans la commercialisation des thérapies cellulaires et l'expertise industrielle approfondie de Shaw devraient guider Kyverna dans sa prochaine phase de croissance, en se concentrant sur la préparation du marché et l'expansion dans le domaine des maladies auto-immunes.

Kyverna Therapeutics (KYTX) hat wichtige Änderungen in der Führung bekannt gegeben. Warner Biddle wurde zum neuen CEO und Vorstandsmitglied ernannt und ersetzt Peter Maag. Biddle bringt über 30 Jahre Erfahrung in der kommerziellen und Franchise-Leitung mit, einschließlich erfolgreicher CAR T-Therapieeinführungen bei Kite Pharma. Christi Shaw, eine erfahrene Führungskraft im Bereich der Lebenswissenschaften, tritt dem Board of Directors bei und folgt auf Brian Kotzin.

Diese Ernennungen sollen die Führung von Kyverna stärken, während das Unternehmen seine CART-Zelltherapien für Autoimmunerkrankungen vorantreibt. Das Hauptkandidat des Unternehmens, KYV-101, schreitet in fortgeschrittene Entwicklungsstadien voran. Biddles Erfahrung in der Kommerzialisierung von Zelltherapien und Shaws umfassende Branchenerfahrung werden erwartet, um Kyverna durch die nächste Wachstumsphase zu führen, mit dem Fokus auf Marktentwicklung und Expansion im Bereich der Autoimmunerkrankungen.

Positive
  • Appointment of Warner Biddle as CEO, bringing 30+ years of commercial and product launch experience in cell therapies
  • Addition of Christi Shaw to the Board, contributing extensive pharmaceutical industry leadership experience
  • KYV-101 advancing to later stages of development, showing promise in 15 indications
  • Strong financial position following successful IPO earlier in the year
Negative
  • Departure of previous CEO Peter Maag and Board member Brian Kotzin, potentially disrupting continuity
  • Significant equity grant to new CEO, potentially diluting existing shareholders

– Warner Biddle Appointed as Chief Executive Officer and to Board of Directors, Bringing Over 30 Years of Commercial, Product Planning and Franchise Leadership Experience, Including Successful Launches for CAR T Pioneer in Hematology

– Christi Shaw, Life Sciences Leader at Multiple Major Pharmaceutical and Biotech Companies and Across Therapeutic Areas, Appointed to Board of Directors

– Together Strengthen Leadership as Trailblazers of Cell Therapy with Extensive Experience Leading Through Clinical Development, Manufacturing, Commercial Launch and Expansion

EMERYVILLE, Calif., Sept. 16, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the appointment of Warner Biddle as the Company's Chief Executive Officer (CEO) and a member of its Board of Directors. Mr. Biddle succeeds Peter Maag, Ph.D., who has resigned from his role as CEO and a member of the Board, effective immediately. In addition, Kyverna announced the appointment of Christi Shaw to its Board of Directors. Ms. Shaw succeeds Brian Kotzin, M.D., who has decided to step down from the Board of Directors.

"Since its inception in 2018, Kyverna has made tremendous progress in pursuit of a paradigm shift for patients with autoimmune disease. Kyverna today sits on the precipice of its next chapter, as KYV-101 is progressing rapidly into later stages of development and embarking on a path to market. This introduces new and exciting opportunities, which Peter and the Board recognized the company must evolve to meet," said Ian Clark, Chairman of the Board of Directors at Kyverna. "I am delighted to welcome Warner Biddle, who brings a broad set of experiences which are the right fit to guide Kyverna into the future. He joins with over 30 years of global experience leading product planning and commercialization, most recently for pioneering CAR T therapies at Kite, and a track record for building successful teams and delivering results. We are also excited to welcome Christi Shaw, whose decades spent in executive roles with portfolio leadership and vast operational scope make her a tremendous addition to our Board of Directors. Together, we believe their rich experience advancing and commercializing cell therapies in hematology will extend Kyverna's leading position for CAR T in autoimmune disease."

Mr. Biddle is a seasoned pharmaceutical executive, with over 30 years of global experience in senior commercial and franchise leadership roles across various products, disease areas and geographies. Most recently, he served as Senior Vice President, Global Head of Commercial at Kite Pharma (a Gilead Company). In this role, Mr. Biddle led multiple product launches and market-building initiatives, driving unprecedented growth for Yescarta® and Tecartus® that established Kite as a leader in the cell therapy market. In addition, in 2023, Mr. Biddle was selected by the Gilead Chairman and CEO to act as interim Head of Kite (CEO), during which time he led Kite's research, development, medical affairs, technical operations, corporate development and G&A functions. Prior to joining Kite in 2020, Mr. Biddle spent a decade at Genentech, where he successfully led the Breast/Gynecology, Skin Cancer and Ophthalmology franchises through multiple launches and line extensions for both large and smaller products including Kadcyla®, Tecentriq®, Erivedge® and Lucentis®. Earlier, Mr. Biddle held senior commercial and franchise leadership roles at Novartis and GlaxoSmithKline (GSK) working in Canada, the United Kingdom and Switzerland. Mr. Biddle holds an Honors Degree in Commerce from the University of Saskatchewan, with a specialization in Marketing and Statistics.

"CAR T therapeutics represent an entirely new therapeutic category in the treatment of autoimmune disease and Kyverna is a leader in this pursuit, with promising clinical programs in development and next-generation innovations on the horizon to further improve administration and accessibility. KYV-101 has already demonstrated encouraging efficacy and safety from an initial dataset across 15 indications, with commercial prospects accelerating for stiff person syndrome and myasthenia gravis, and still much broader potential to serve more than 8 million patients with B cell-driven diseases," said Mr. Biddle. "I am excited to join the company at this pivotal stage in its growth and to build on the strong foundation already in place at Kyverna. I have seen firsthand the transformative impact of CAR T therapeutics on patients' lives and am eager to work alongside this team to extend the reach of CAR T therapies to many more patients and bring them the innovations they are waiting for."

Ms. Shaw has spent more than 30 years in executive leadership roles across the industry's largest pharmaceutical companies and a broad range of therapeutic areas. Most recently, Ms. Shaw served as the Chief Executive Officer of Kite. Earlier, Ms. Shaw served as Senior Vice President of Eli Lilly Company and President of Lilly Bio-Medicines, the business within Eli Lilly Company that comprises neuroscience and immunology. Previously, Ms. Shaw was an executive at Novartis Pharmaceutical Corporation, including as U.S. country head and President of Novartis Pharmaceutical Corporation and as North American region head of Novartis Oncology, and earlier held leadership roles of increasing responsibility at Johnson & Johnson, Inc. Ms. Shaw currently serves on the board of directors of Avantor, Beam Therapeutics and ReAlta Lifesciences, and is an advisor to Cellares and the Iowa State Ivy College of Business. In addition, she is the co-founder of the More Moments More Memories Foundation to assist people with cancer and their caregivers. Ms. Shaw holds an M.B.A. from the University of Wisconsin and a B.B.A. in Marketing from Iowa State University.

Mr. Clark added, "On behalf of the Board, I also want to extend our thanks to Peter for his leadership of Kyverna. Over the past two years, Peter laid a strong foundation for the company, translating exploratory science into a robust clinical program across several indications, and establishing strong financial footing with a successful initial public offering earlier this year. We appreciate his contributions and wish him the best in his future endeavors."

Inducement Grant

In connection with the appointment of Mr. Biddle as Kyverna's Chief Executive Officer and a member of its Board of Directors, on September 16, 2024, Kyverna granted Mr. Biddle an option to purchase 2,579,259 shares of its common stock (Option). The Option was granted pursuant to the Kyverna Therapeutics, Inc. 2024 Inducement Equity Incentive Plan, as approved by the compensation committee of Kyverna's Board of Directors on September 14, 2024, and was granted as an inducement material to Mr. Biddle's employment with Kyverna in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price of the Option will be the closing price of Kyvenra's common stock on September 16, 2024, the date of grant. The Option will vest over four years, with 25% of the total number of shares subject to the Option vesting on the one-year anniversary of Mr. Biddle's appointment and 1/48th of the total number of shares subject to the Option vesting monthly thereafter, subject in each case to Mr. Biddle's continued service to Kyverna on each vesting date. Kyverna is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Kyverna Therapeutics

 Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. 

Our lead CAR T-cell therapy candidate, KYV-101, is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis. 

Kyverna's pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

Forward-Looking Statements

 Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." The words, without limitation, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to:  leadership transition matters; KYV-101's safety, efficacy and commercial prospects; Kyverna's ongoing clinical trials; Kyverna's pipeline and the potential for Kyverna's CAR T-cell therapies to be well suited for use in B cell-driven autoimmune diseases. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of Kyverna's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna's management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. 

For more information, please visit https://kyvernatx.com.

Contact:

Precision AQ on behalf of Kyverna Therapeutics
Investors: InvestorRelations@kyvernatx.com
Media: media@kyvernatx.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/kyverna-therapeutics-announces-leadership-update-302248575.html

SOURCE Kyverna Therapeutics

FAQ

Who is the new CEO of Kyverna Therapeutics (KYTX)?

Warner Biddle has been appointed as the new Chief Executive Officer of Kyverna Therapeutics (KYTX), effective September 16, 2024.

What is Kyverna Therapeutics' (KYTX) main focus?

Kyverna Therapeutics (KYTX) is focused on developing CAR T cell therapies for patients suffering from autoimmune diseases.

What is the current status of Kyverna's (KYTX) lead product candidate?

Kyverna's (KYTX) lead product candidate, KYV-101, is progressing rapidly into later stages of development and has shown encouraging efficacy and safety data across 15 indications.

Who was added to Kyverna Therapeutics' (KYTX) Board of Directors?

Christi Shaw, a life sciences leader with experience at major pharmaceutical and biotech companies, was appointed to Kyverna Therapeutics' (KYTX) Board of Directors.

Kyverna Therapeutics, Inc.

NASDAQ:KYTX

KYTX Rankings

KYTX Latest News

KYTX Stock Data

215.21M
38.37M
10.78%
76.16%
5.36%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
EMERYVILLE